PEGylated tyrosyl-tRNA synthetase polypeptides
The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.
1. A PEGylated tyrosyl-tRNA synthetase (YRS) polypeptide selected from,
(a) a YRS polypeptide consisting of a sequence that is at least 95% identical to the sequence set forth in SEQ ID NO:7 YRS(1-353), which is modified by A4C, C67S, and C250S substitutions, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to A4C;
(b) a YRS polypeptide consisting of a sequence that is at least 98% identical to the sequence set forth in SEQ ID NO:7 YRS(1-353), which is modified by A4C, C67S, and C250S substitutions, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to A4C;
(c) a YRS polypeptide consisting of the sequence set forth in SEQ ID NO:7 YRS(1-353), which is modified by A4C, C67S, and C250S substitutions, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to A4C;
(d) a YRS polypeptide consisting of a sequence that is at least 95% identical to the sequence set forth in SEQ ID NO:7 YRS(1-353), which is modified by C67S, C250S, and A351C substitutions, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to A351C;
(e) a YRS polypeptide consisting of a sequence that is at least 98% identical to the sequence set forth in SEQ ID NO:7 YRS(1-353), which is modified by C67S, C250S, and A351C substitutions, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to A351; and
(f) a YRS polypeptide consisting of the sequence set forth in SEQ ID NO:7 YRS(1-353), which is modified by C67S, C250S, and A351C substitutions, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to A351C.
2. The PEGylated YRS polypeptide of claim 1 , wherein the PEGylated product exhibits a higher specific activity in a charging assay compared to the non PEGylated protein.
3. The PEGylated YRS polypeptide of claim 1 , comprising the structure:
4. The PEGylated YRS polypeptide of claim 1 , comprising the structure:
5. The PEGylated YRS polypeptide of claim 1 :
6. The PEGylated YRS polypeptide of claim 1 :
7. The PEGylated YRS polypeptide of claim 1 , wherein the YRS polypeptide has substantially the same secondary structure as unmodified YRS polypeptide, as determined via UV circular dichroism analysis.
8. The PEGylated YRS polypeptide of claim 1 , wherein the PEGylated YRS polypeptide has a plasma or sera pharmacokinetic AUC profile at least 5-fold greater than unmodified YRS polypeptide when administered to rats.
9. The PEGylated YRS polypeptide of claim 1 , wherein the PEGylated YRS polypeptide has greater than 2 fold the activity of the unPEGylated protein in a charging assay.
10. The PEGylated YRS polypeptide of claim 1 , wherein the PEGylated YRS polypeptide has greater than 3 fold the activity of the unPEGylated protein in a charging assay.
11. The PEGylated YRS polypeptide of claim 1 , wherein the PEGylated YRS polypeptide has greater than 4 fold the activity of the unPEGylated protein in a charging assay.
12. A dosing regimen which maintains an average steady-state concentration of YRS polypeptide in the subjects's plasma of between about 0.3 μg/ml and about 3 μg/ml when using a dosing interval of 3 days or longer, comprising administering to the patient a therapeutic dose of PEGylated YRS polypeptide of any of claim 1 .
13. A method for maintaining YRS polypeptide levels above the minimum effective therapeutic level in a subject in need thereof, comprising administering to the subject a therapeutic dose of PEGylated YRS polypeptide of claim 1 .
14. A method for treating a hematopoiesis related disease in a subject in need thereof, comprising administering to the subject a therapeutic dose of PEGylated YRS polypeptide of claim 1 .
15. The method of claim 14 , wherein the hematopoiesis related disease is selected from thrombocytopenia, lymphocytopenia, neutropenia, basopenia, eosinopenia, anemias, polycythemia, neutrophilia, eosinophilia, or basophilia.
16. A method for treating a subject with a myelodysplastic syndrome comprising administering to the subject a therapeutic dose of PEGylated YRS polypeptide of claim 1 and a pharmaceutically acceptable carrier.
17. The method of claim 16 , wherein the myelodysplastic syndrome is selected from Refractory Anemia (RA)(ICD-O code M9980/3), Refactory cytopenia with unilineage dysplasia (Refactory anemia, Refactory neutropenia, and Refractory thrombocytopenia), Refractory Anemia with Ring Sideroblasts (RARS) (ICD-O code M9982/3), Refractory Anemia with Ring Sideroblasts thrombocytosis, Refractory cytopenia with multilineage dysplasia (RCMD), Refractory Anemia with Excess Blasts (RAEB) (ICD-O code M9983/3), Refractory Anemia with Excess Blasts I or II, Refractory Anemia with Excess Blasts in Transformation (RAEB-T) (ICD-O code M9984/3), Chronic Myelomoncytic Leukemia (CMML) (ICD-O code M9945/3), 5q-syndrome, myelodysplastic-myeloproliferative overlap syndromes, Myelodysplasia unclassifiable, and refractory cytopenia of childhood.
18. A pharmaceutical composition comprising a PEGylated tyrosyl-tRNA synthetase (YRS) polypeptide of claim 1 and a pharmaceutically acceptable carrier or excipient.
19. The pharmaceutical composition of claim 18 , wherein the composition is buffered to a pH of about 5.5 to about 6.5.
20. The pharmaceutical composition of claim 18 , wherein the composition is buffered to a pH of about 6.0.
21. The pharmaceutical composition of claim 18 , wherein the composition is buffered with a phosphate buffer at a concentration of about 10 to 20 mM.
22. The pharmaceutical composition of claim 18 , wherein the composition is characterized by decreased aggregation of the PEGylated YRS polypeptides of any of claims 3 to 6 compared to a composition incubated under identical conditions but at pH 7.0 or higher.